Related references
Note: Only part of the references are listed.Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
Patrick Rossignol et al.
CIRCULATION (2012)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Frank A. Holtkamp et al.
KIDNEY INTERNATIONAL (2011)
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
Jean-Philippe Bertocchio et al.
KIDNEY INTERNATIONAL (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
Maartje C. J. Slagman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Aldosterone: effects on the kidney and cardiovascular system
Marie Briet et al.
NATURE REVIEWS NEPHROLOGY (2010)
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?
Michael Gekle et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2009)
Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
Yoshiyuki Furumatsu et al.
HYPERTENSION RESEARCH (2008)
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
Liffert Vogt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
S. Bianchi et al.
KIDNEY INTERNATIONAL (2006)
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors
Miki Nagase et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function
Anton H. van den Meiracker et al.
JOURNAL OF HYPERTENSION (2006)
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
Murray Epstein et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
K. J. Schjoedt et al.
KIDNEY INTERNATIONAL (2006)
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker
Anastasia Chrysostomou et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Beneficial impact of spironolactone in diabetic nephropathy
KJ Schjoedt et al.
KIDNEY INTERNATIONAL (2005)
Regression of existing glomerulosclerosis by inhibition of aldosterone
JC Aldigier et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy - A randomized, double-masked, cross-over study
K Rossing et al.
DIABETES CARE (2005)
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
G Fujisawa et al.
KIDNEY INTERNATIONAL (2004)
Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration
RB de Paula et al.
HYPERTENSION (2004)
被撤回的出版物: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study (Retracted article see vol 23, pg 818, 2006)
R Rachmani et al.
DIABETIC MEDICINE (2004)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
